B-ENT

HPV-related oropharyngeal cancers in Flanders (Belgium): a multicenter study

1.

Department of Radiation Oncology, UH Leuven, Leuven, Belgium

2.

Lab of Experimental Radiotherapy, KU Leuven, Leuven, Belgium

3.

Interuniversity Institute for Biostatistics and Statistical Bioinformatics, KU Leuven, Leuven, Belgium

4.

Department of Pathology, UH Leuven, Leuven, Belgium

5.

Department of Radiation Oncology, ZNA Middelheim, Antwerp, Antwerp Belgium

6.

Department of Radiation Oncology, UH Brussels, Jette, Brussels, Belgium

7.

Department of Radiation Oncology, UH Ghent, Ghent,Belgium

B-ENT 2014; 10: 7-14
Read: 988 Downloads: 784 Published: 05 February 2020

HPV-related oropharyngeal cancers in Flanders Belgium): A multicenter study. Introduction: Human papilloma virus (HPV) was recently reported to play a major role in oropharyngeal carcinoma. Large geographical differences in the disease prevalence have been described. Until now, no data have been reported for Flanders (Belgium).

Methods: A multicenter cooperative study was undertaken at the radiation-oncology departments of Flemish universities. Tumor blocks from patients diagnosed with oropharyngeal carcinoma between 2000 and 2010 were tested for HPV at a single center. Patients’ characteristics, treatments, and follow-up data were recorded from medical files. Age standardized incidence rates of oropharyngeal carcinoma were collected from the Belgian Cancer Registry.

Results and conclusions: The incidence of oropharyngeal carcinoma has increased in males and females. Tissues were collected from 264 patients and the HPV status could be defined in 249 of them. The prevalence of HPV(+) oropharyngeal carcinoma was 24.78% (19.93-30.36%). In our cohort, HPV(+) tumors occurred in patients with more advanced tumor stages (p < 0.05), who smoked less (p < 0.05), consumed less alcohol (p < 0.05), had a tonsillar/base of tongue sublocalization (p < 0.05), and were older (p < 0.05). After radiotherapy, locoregional control and disease free survival were significantly better for patients with HPV(+) status (p < 0.05) in univariate analysis. HPV status remained a strong predictor of better locoregional control after multivariate analysis. We found that concurrent chemotherapy had an equal benefit for locoregional control in both HPV(+) and HPV(-) patients.

Files
EISSN 2684-4907